Journal of Clinical and Translational Endocrinology最新文献_第3页

Collagen in pituitary adenomas: A comprehensive review of biological roles and clinical implications 胶原蛋白在垂体腺瘤中的生物学作用和临床意义的综合综述

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Clinical and Translational Endocrinology

Pub Date : 2025-07-10 DOI: 10.1016/j.jcte.2025.100408

Jie Liu , Yong Yao , Lian Duan , Lin Lu , Huijuan Zhu , Yongning Li , Jun Gao

Pituitary adenomas (PAs) are common brain tumors, accounting for about 15% of all brain neoplasms. Although generally benign, they can lead to serious complications through mass effects and hormone dysregulation. Emerging evidence suggests that collagen, a major component of the extracellular matrix (ECM), plays a pivotal role in PA pathophysiology. Collagen provides both structural integrity and biochemical cues within the tumor microenvironment (TME), influencing cellular behaviors and intercellular interactions. Recent studies indicate that collagen remodeling in PAs is dynamic, with alterations in collagen composition and organization affecting tumor growth, invasion, and hormone secretion. Collagen degradation products and collagenase activity may also facilitate tumor invasion into adjacent tissues. Additionally, collagen has been implicated in immune modulation, acting as a physical barrier that restricts immune cell infiltration and promotes immune evasion through receptor-mediated signaling. Metabolically, collagen may serve as an energy source or modulate metabolic pathways to sustain tumor proliferation. Clinically, collagen content in PAs correlates with tumor consistency, which has implications for surgical resection strategies. Moreover, serum collagen is emerging as a potential non-invasive biomarker for PA diagnosis and prognosis. Targeting collagen synthesis, degradation, or its mechanotransductive signaling pathways represents a promising therapeutic avenue.

垂体腺瘤（PAs）是常见的脑肿瘤，约占所有脑肿瘤的15%。虽然通常是良性的，但它们可以通过质量效应和激素失调导致严重的并发症。越来越多的证据表明，胶原蛋白是细胞外基质（ECM）的主要成分，在PA病理生理中起着关键作用。胶原蛋白在肿瘤微环境（TME）中提供结构完整性和生化线索，影响细胞行为和细胞间相互作用。最近的研究表明，PAs中的胶原重塑是动态的，胶原成分和组织的改变影响肿瘤的生长、侵袭和激素分泌。胶原降解产物和胶原酶活性也可能促进肿瘤侵入邻近组织。此外，胶原蛋白与免疫调节有关，它作为一种物理屏障，限制免疫细胞浸润，并通过受体介导的信号传导促进免疫逃避。在代谢方面，胶原蛋白可以作为能量来源或调节代谢途径来维持肿瘤增殖。临床上，PAs中胶原蛋白含量与肿瘤一致性相关，这对手术切除策略有影响。此外，血清胶原蛋白正在成为PA诊断和预后的潜在非侵入性生物标志物。靶向胶原合成、降解或其机械转导信号通路是一种很有前途的治疗途径。

{"title":"Collagen in pituitary adenomas: A comprehensive review of biological roles and clinical implications","authors":"Jie Liu , Yong Yao , Lian Duan , Lin Lu , Huijuan Zhu , Yongning Li , Jun Gao","doi":"10.1016/j.jcte.2025.100408","DOIUrl":"10.1016/j.jcte.2025.100408","url":null,"abstract":"<div><div>Pituitary adenomas (PAs) are common brain tumors, accounting for about 15% of all brain neoplasms. Although generally benign, they can lead to serious complications through mass effects and hormone dysregulation. Emerging evidence suggests that collagen, a major component of the extracellular matrix (ECM), plays a pivotal role in PA pathophysiology. Collagen provides both structural integrity and biochemical cues within the tumor microenvironment (TME), influencing cellular behaviors and intercellular interactions. Recent studies indicate that collagen remodeling in PAs is dynamic, with alterations in collagen composition and organization affecting tumor growth, invasion, and hormone secretion. Collagen degradation products and collagenase activity may also facilitate tumor invasion into adjacent tissues. Additionally, collagen has been implicated in immune modulation, acting as a physical barrier that restricts immune cell infiltration and promotes immune evasion through receptor-mediated signaling. Metabolically, collagen may serve as an energy source or modulate metabolic pathways to sustain tumor proliferation. Clinically, collagen content in PAs correlates with tumor consistency, which has implications for surgical resection strategies. Moreover, serum collagen is emerging as a potential non-invasive biomarker for PA diagnosis and prognosis. Targeting collagen synthesis, degradation, or its mechanotransductive signaling pathways represents a promising therapeutic avenue.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100408"},"PeriodicalIF":4.2,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144614279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor 治疗囊性纤维化相关性糖尿病成人患者胰岛素剂量调整的血红蛋白A1c

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Clinical and Translational Endocrinology

Pub Date : 2025-07-02 DOI: 10.1016/j.jcte.2025.100407

Espérie Burnet , Deborah Grunewald , Etienne Larger , Florence Camus-Bablon , Catherine Eisenhauer , François Mifsud , Clémence Martin , Isabelle Honoré , Reem Kanaan , Nicolas Carlier , Johanna Fesenbeckh , Helen Mosnier-Pudar , Pierre-Régis Burgel

Background

Elexacaftor-tezacaftor-ivacaftor (ETI) became available for adults with cystic fibrosis (CF) in 2019, but its impact on CF-related diabetes (CFRD) remains unclear.

Methods

A single-center retrospective cohort study was conducted among adults with CFRD to examine the change in insulin dose-adjusted Hemoglobin A1c (IDAA1c). Linear mixed effects model (LMEM) analysis was used to investigate the change in IDAA1c between baseline and 24 months of follow up, comparing an ETI-treated group to an unexposed group. Baseline values were those documented at treatment initiation for the ETI-treated group and in March 2020 (±3 months) for the unexposed group.

Results

A total of 49 adults were included, 39 were treated with ETI and 10 were not. Median [Interquartile range] time since CFRD diagnosis at baseline was 13 [7–18] and 14 [10–18] years, respectively (p = 0.610). In the ETI-treated group, mean weight increased by a 4.44 kg (95 % Confidence Interval, 95 %CI: 3.08 to 5.79, p < 0.001), insulin total daily dose decreased by 5 units (95 %CI: −9 to 0, p = 0.033), and hemoglobin A1c (%) decreased by 0.65 points (95 %CI: −0.96 to −0.34, p < 0.001). No change was observed in the unexposed group. LMEM analysis found a numerically significant association between ETI and decreased IDAA1c, estimated at −1.14 points (95 %CI: −2.35 to 0.06, p = 0.067) after adjusting for age, sex, time since CFRD diagnosis and the introduction of Metformin.

Conclusion

A numerically significant association between ETI and IDAA1c decrease was observed in adults with established CFRD after 24 months of treatment, suggesting ETI contributed to improved glycemic control.

2019年，delexacaftor - tezactor -ivacaftor （ETI）开始用于囊性纤维化（CF）成人患者，但其对CF相关糖尿病（CFRD）的影响尚不清楚。方法对成年CFRD患者进行单中心回顾性队列研究，观察胰岛素剂量调整血红蛋白A1c （IDAA1c）的变化。采用线性混合效应模型（LMEM）分析研究基线和随访24个月期间IDAA1c的变化，并将eti治疗组与未暴露组进行比较。基线值是治疗组在治疗开始时和未暴露组在2020年3月（±3个月）记录的基线值。结果共纳入49例成人，其中39例经ETI治疗，10例未行ETI治疗。基线诊断CFRD的中位时间[四分位数范围]分别为13[7-18]和14[10-18]年（p = 0.610）。在eti治疗组，平均体重增加了4.44 kg(95%置信区间，95% CI: 3.08至5.79,p <；0.001)，胰岛素总日剂量降低了5个单位（95% CI: - 9 ~ 0, p = 0.033），血红蛋白A1c（%）降低了0.65点(95% CI: - 0.96 ~ - 0.34, p <；0.001)。未暴露组未观察到任何变化。LMEM分析发现，在调整年龄、性别、CFRD诊断后的时间和引入二甲双胍后，ETI和IDAA1c降低之间存在显著的数值相关性，估计为- 1.14点（95% CI: - 2.35至0.06,p = 0.067）。结论在治疗24个月后，确诊CFRD的成人患者观察到ETI与IDAA1c降低之间的数值显著相关，表明ETI有助于改善血糖控制。

{"title":"Decreased insulin dose-adjusted hemoglobin A1c in adults with cystic fibrosis-related diabetes treated with elexacaftor-tezacaftor-ivacaftor","authors":"Espérie Burnet , Deborah Grunewald , Etienne Larger , Florence Camus-Bablon , Catherine Eisenhauer , François Mifsud , Clémence Martin , Isabelle Honoré , Reem Kanaan , Nicolas Carlier , Johanna Fesenbeckh , Helen Mosnier-Pudar , Pierre-Régis Burgel","doi":"10.1016/j.jcte.2025.100407","DOIUrl":"10.1016/j.jcte.2025.100407","url":null,"abstract":"<div><h3>Background</h3><div>Elexacaftor-tezacaftor-ivacaftor (ETI) became available for adults with cystic fibrosis (CF) in 2019, but its impact on CF-related diabetes (CFRD) remains unclear.</div></div><div><h3>Methods</h3><div>A single-center retrospective cohort study was conducted among adults with CFRD to examine the change in insulin dose-adjusted Hemoglobin A1c (IDAA1c). Linear mixed effects model (LMEM) analysis was used to investigate the change in IDAA1c between baseline and 24 months of follow up, comparing an ETI-treated group to an unexposed group. Baseline values were those documented at treatment initiation for the ETI-treated group and in March 2020 (±3 months) for the unexposed group.</div></div><div><h3>Results</h3><div>A total of 49 adults were included, 39 were treated with ETI and 10 were not. Median [Interquartile range] time since CFRD diagnosis at baseline was 13 [7–18] and 14 [10–18] years, respectively (p = 0.610). In the ETI-treated group, mean weight increased by a 4.44 kg (95 % Confidence Interval, 95 %CI: 3.08 to 5.79, p < 0.001), insulin total daily dose decreased by 5 units (95 %CI: −9 to 0, p = 0.033), and hemoglobin A1c (%) decreased by 0.65 points (95 %CI: −0.96 to −0.34, p < 0.001). No change was observed in the unexposed group. LMEM analysis found a numerically significant association between ETI and decreased IDAA1c, estimated at −1.14 points (95 %CI: −2.35 to 0.06, p = 0.067) after adjusting for age, sex, time since CFRD diagnosis and the introduction of Metformin.</div></div><div><h3>Conclusion</h3><div>A numerically significant association between ETI and IDAA1c decrease was observed in adults with established CFRD after 24 months of treatment, suggesting ETI contributed to improved glycemic control.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100407"},"PeriodicalIF":4.2,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144571328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma 细胞分裂周期20促进肿瘤进展并预测儿童和成人肾上腺皮质癌的不良临床预后

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Clinical and Translational Endocrinology

Pub Date : 2025-07-02 DOI: 10.1016/j.jcte.2025.100406

Jiahong Chen , Peisheng Huang , Yongcheng Shi , Shanshan Mo , Cheng-Ya Hsu , Shumin Fang , Chuanfan Zhong , Le Zhang , Lanting Zuo , Jianming Lu , Weide Zhong , Zhuoya Huang , Zhong Dong

Background

Adrenocortical carcinoma (ACC) is an uncommon and highly aggressive tumor with a grim prognosis. Numerous investigations have elucidated a close association between the dysregulated expression of multiple genes within tumors and the initiation as well as progression of neoplasms. These dysregulated genes not only exert pivotal roles in tumorigenesis but also harbor significant potential as prognostic biomarkers.

Methods

This study utilized transcriptomic data from public databases of ACC and normal tissue samples to screen for differentially expressed genes (DEGs). Subsequently, univariate Cox regression and receiver operating characteristic (ROC) curve were employed to identify potential prognostic biomarkers for ACC. Immunohistochemistry and in vitro cell experiments were conducted to validate the expression and potential functions of Cell division cycle 20 (CDC20) in ACC cells. Additionally, we analyzed the relationship between CDC20 and CD8+ T cells, immunotherapy response, somatic mutations, and copy number variations.

Results

CDC20 has emerged as an independent adverse prognostic factor in ACC, with significantly elevated expression levels. In vitro cell experiments have demonstrated that downregulation of CDC20 expression suppresses proliferation and migration of ACC cells. Notably, our study has identified CDC20 expression as most closely associated with TP53 mutation. Additionally, CDC20 expression levels exhibit a negative correlation with infiltration of CD8+ T cells. Patients with low CDC20 expression may show improved response to anti-PD-1 immunotherapy.

Conclusion

CDC20 serves as a reliable and robust biomarker in ACC, playing a crucial role in predicting survival outcomes and assessing immunotherapy response in adult and childhood ACC patients.

背景肾上腺皮质癌（ACC）是一种罕见的高侵袭性肿瘤，预后恶劣。许多研究已经阐明了肿瘤内多种基因表达失调与肿瘤的发生和发展之间的密切联系。这些失调基因不仅在肿瘤发生中发挥关键作用，而且作为预后生物标志物具有重要的潜力。方法利用ACC公共数据库和正常组织样本的转录组学数据筛选差异表达基因（DEGs）。随后，采用单变量Cox回归和受试者工作特征（ROC）曲线来确定ACC的潜在预后生物标志物。通过免疫组织化学和体外细胞实验验证细胞分裂周期20 （CDC20）在ACC细胞中的表达及其潜在功能。此外，我们分析了CDC20和CD8+ T细胞、免疫治疗反应、体细胞突变和拷贝数变化之间的关系。结果scdc20已成为ACC中独立的不良预后因素，其表达水平显著升高。体外细胞实验表明，下调CDC20表达可抑制ACC细胞的增殖和迁移。值得注意的是，我们的研究已经确定CDC20表达与TP53突变最密切相关。此外，CDC20表达水平与CD8+ T细胞浸润呈负相关。低CDC20表达的患者可能对抗pd -1免疫治疗有更好的反应。结论cdc20是一种可靠的ACC生物标志物，在预测成人和儿童ACC患者的生存结局和评估免疫治疗反应中起着至关重要的作用。

{"title":"Cell division cycle 20 promotes tumor progression and predicts poor clinical outcome in childhood and adult adrenocortical carcinoma","authors":"Jiahong Chen , Peisheng Huang , Yongcheng Shi , Shanshan Mo , Cheng-Ya Hsu , Shumin Fang , Chuanfan Zhong , Le Zhang , Lanting Zuo , Jianming Lu , Weide Zhong , Zhuoya Huang , Zhong Dong","doi":"10.1016/j.jcte.2025.100406","DOIUrl":"10.1016/j.jcte.2025.100406","url":null,"abstract":"<div><h3>Background</h3><div>Adrenocortical carcinoma (ACC) is an uncommon and highly aggressive tumor with a grim prognosis. Numerous investigations have elucidated a close association between the dysregulated expression of multiple genes within tumors and the initiation as well as progression of neoplasms. These dysregulated genes not only exert pivotal roles in tumorigenesis but also harbor significant potential as prognostic biomarkers.</div></div><div><h3>Methods</h3><div>This study utilized transcriptomic data from public databases of ACC and normal tissue samples to screen for differentially expressed genes (DEGs). Subsequently, univariate Cox regression and receiver operating characteristic (ROC) curve were employed to identify potential prognostic biomarkers for ACC. Immunohistochemistry and in vitro cell experiments were conducted to validate the expression and potential functions of Cell division cycle 20 (CDC20) in ACC cells. Additionally, we analyzed the relationship between CDC20 and CD8+ T cells, immunotherapy response, somatic mutations, and copy number variations.</div></div><div><h3>Results</h3><div>CDC20 has emerged as an independent adverse prognostic factor in ACC, with significantly elevated expression levels. In vitro cell experiments have demonstrated that downregulation of CDC20 expression suppresses proliferation and migration of ACC cells. Notably, our study has identified CDC20 expression as most closely associated with TP53 mutation. Additionally, CDC20 expression levels exhibit a negative correlation with infiltration of CD8+ T cells. Patients with low CDC20 expression may show improved response to anti-PD-1 immunotherapy.</div></div><div><h3>Conclusion</h3><div>CDC20 serves as a reliable and robust biomarker in ACC, playing a crucial role in predicting survival outcomes and assessing immunotherapy response in adult and childhood ACC patients.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100406"},"PeriodicalIF":4.2,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144549894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated glucose levels in melanoma patients − a real-world analysis 黑色素瘤患者血糖水平升高——现实世界的分析

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Clinical and Translational Endocrinology

Pub Date : 2025-06-26 DOI: 10.1016/j.jcte.2025.100405

Joan Walter , Bojan Bojanic , Manuel Dittli , Nadia Fehr , Thomas Sartoretti , Moritz Schwyzer , Katharina Binz , Antonio G. Gennari , Matthias Ernst , Martin W. Huellner , Michael Messerli

Aim

To assess the glycemic status of consecutive melanoma patients undergoing standardized capillary fasting blood glucose (cFBG) assessment prior to fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) examination.

Methods

This retrospective study included 336 consecutive melanoma patients at the University Hospital Zurich, Switzerland. Fasting cFBG levels were measured prior to FDG PET/CT and classified according to American Diabetes Association guidelines. Multivariable linear regression analysis was performed to identify independent predictors of cFBG levels. Sensitivity analyses were performed on patients examined before 11 AM and fasting for 8 h as well as patients without known diabetes.

Results

The cohort included 336 melanoma patients with a median age of 67 years (IQR 57–76), 36 % female (122/336), and 12 % (40/336) with known diabetes mellitus. The median cFBG was 103 mg/dL (IQR 94–112; 5.7 mmol/L, IQR 5.2–6.2). Overall, 58 % (194/336) of patients had non-normal cFBG levels (≥100 mg/dL; ≥5.6 mmol/L), consistent with findings from a sensitivity analysis of patients presenting before 11 AM, where 58 % (115/198) exhibited non-normal levels. Excluding patients with known diabetes, 56 % (165/296) of patients had non-normal cFBG levels, with 7 % (20/210) having levels ≥126 mg/dL (≥7.0 mmol/L), indicative of possible undiagnosed diabetes mellitus. Multivariable linear regression analysis identified male gender, active disease, and subcutaneous fat as independent predictors of cFBG levels, whereas traditional risk factors such as BMI, visceral fat, hypertension or lack of exercise were not independent predictors.

Conclusion

More than half of melanoma patients have elevated cFBG levels, even in those without known diabetes, highlighting the need for improved glycemic screening and management.

目的评估连续黑色素瘤患者在氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描（FDG PET/CT）检查前进行标准化毛细血管空腹血糖（cFBG）评估的血糖状况。方法本回顾性研究纳入瑞士苏黎世大学医院336例黑色素瘤患者。空腹空腹空腹血糖水平在FDG PET/CT之前测量，并根据美国糖尿病协会指南进行分类。进行多变量线性回归分析以确定cFBG水平的独立预测因子。对上午11点前检查并禁食8小时的患者以及没有已知糖尿病的患者进行敏感性分析。结果该队列包括336例黑色素瘤患者，中位年龄为67岁（IQR 57-76）， 36%为女性（122/336），12%（40/336）患有已知的糖尿病。中位cFBG为103 mg/dL (IQR 94-112；5.7 mmol/L, IQR 5.2-6.2)。总体而言，58%（194/336）的患者cFBG水平异常(≥100mg /dL；≥5.6 mmol/L)，与上午11点前就诊的患者的敏感性分析结果一致，其中58%（115/198）表现出异常水平。排除已知糖尿病患者，56%（165/296）患者的cFBG水平异常，7%（20/210）患者的cFBG水平≥126 mg/dL(≥7.0 mmol/L)，表明可能患有未确诊的糖尿病。多变量线性回归分析发现，男性性别、活动性疾病和皮下脂肪是cFBG水平的独立预测因素，而BMI、内脏脂肪、高血压或缺乏运动等传统危险因素不是独立预测因素。结论：超过一半的黑色素瘤患者cFBG水平升高，即使在没有已知糖尿病的患者中也是如此，这突出了改善血糖筛查和管理的必要性。

{"title":"Elevated glucose levels in melanoma patients − a real-world analysis","authors":"Joan Walter , Bojan Bojanic , Manuel Dittli , Nadia Fehr , Thomas Sartoretti , Moritz Schwyzer , Katharina Binz , Antonio G. Gennari , Matthias Ernst , Martin W. Huellner , Michael Messerli","doi":"10.1016/j.jcte.2025.100405","DOIUrl":"10.1016/j.jcte.2025.100405","url":null,"abstract":"<div><h3>Aim</h3><div>To assess the glycemic status of consecutive melanoma patients undergoing standardized capillary fasting blood glucose (cFBG) assessment prior to fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) examination.</div></div><div><h3>Methods</h3><div>This retrospective study included 336 consecutive melanoma patients at the University Hospital Zurich, Switzerland. Fasting cFBG levels were measured prior to FDG PET/CT and classified according to American Diabetes Association guidelines. Multivariable linear regression analysis was performed to identify independent predictors of cFBG levels. Sensitivity analyses were performed on patients examined before 11 AM and fasting for 8 h as well as patients without known diabetes.</div></div><div><h3>Results</h3><div>The cohort included 336 melanoma patients with a median age of 67 years (IQR 57–76), 36 % female (122/336), and 12 % (40/336) with known diabetes mellitus. The median cFBG was 103 mg/dL (IQR 94–112; 5.7 mmol/L, IQR 5.2–6.2). Overall, 58 % (194/336) of patients had non-normal cFBG levels (≥100 mg/dL; ≥5.6 mmol/L), consistent with findings from a sensitivity analysis of patients presenting before 11 AM, where 58 % (115/198) exhibited non-normal levels. Excluding patients with known diabetes, 56 % (165/296) of patients had non-normal cFBG levels, with 7 % (20/210) having levels ≥126 mg/dL (≥7.0 mmol/L), indicative of possible undiagnosed diabetes mellitus. Multivariable linear regression analysis identified male gender, active disease, and subcutaneous fat as independent predictors of cFBG levels, whereas traditional risk factors such as BMI, visceral fat, hypertension or lack of exercise were not independent predictors.</div></div><div><h3>Conclusion</h3><div>More than half of melanoma patients have elevated cFBG levels, even in those without known diabetes, highlighting the need for improved glycemic screening and management.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100405"},"PeriodicalIF":4.2,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144518468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SGLT2 inhibitor therapy in overweight and obese patients with cystic fibrosis-related diabetes: Case series SGLT2抑制剂治疗超重和肥胖伴有囊性纤维化相关性糖尿病患者：病例系列

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Clinical and Translational Endocrinology

Pub Date : 2025-06-23 DOI: 10.1016/j.jcte.2025.100403

Ammar Ahmed , Roshini Asirvatham , Jagdeesh Ullal , Amir Moheet

Cystic fibrosis-related diabetes (CFRD) is the most prevalent extrapulmonary comorbidity in CF. While insulin remains the standard treatment, increasing rates of overweight and obesity due to CFTR modulators highlight the need for new therapies. SGLT2 inhibitors, effective in type 2 diabetes, have not been studied in CFRD. This case series presents eight CFRD patients treated with SGLT2 inhibitors alongside insulin for one year. Half had BMI reductions (1.33–2.89 kg/m2); others had increases. Glycemic control improved in six, worsened in two due to insulin nonadherence. Insulin adjustments showed no pattern. One patient discontinued due to genital infections; overall tolerance was high.

囊性纤维化相关性糖尿病（CFRD）是CF中最常见的肺外合共病。虽然胰岛素仍是标准治疗方法，但由于CFTR调节剂导致超重和肥胖的发生率不断上升，这凸显了对新治疗方法的需求。SGLT2抑制剂对2型糖尿病有效，但尚未在CFRD中进行研究。本病例系列介绍了8例CFRD患者使用SGLT2抑制剂和胰岛素治疗一年。一半的人BMI下降（1.33-2.89 kg/m2）；其他国家则有所增长。6名患者血糖控制得到改善，2名患者因胰岛素不依从而恶化。胰岛素调节没有显示出规律。1名患者因生殖器感染停止治疗；总体耐受性高。

引用次数: 0

Predicting accelerated fetal growth in pregnancy: beyond maternal hyperglycemia – The role of prothymosin-α, inflammatory cytokines, and angiogenic factors 预测妊娠期胎儿生长加速：超越母体高血糖-胸腺蛋白酶-α、炎症细胞因子和血管生成因子的作用

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Clinical and Translational Endocrinology

Pub Date : 2025-06-20 DOI: 10.1016/j.jcte.2025.100404

Maria Mirabelli , Marta Greco , Stefano Iuliano , Francesco Dragone , Eusebio Chiefari , Daniela Foti , Antonio Brunetti

Aim: This study investigates prothymosin-α (ProT-α), an immunomodulatory protein, as a potential biomarker for insulin resistance in gestational diabetes (GDM), and as a predictor of fetal growth by 20 weeks of gestation (wg). Methods: Forty-six women with singleton pregnancies were classified into GDM (n = 8) and normal glucose tolerance (NGT; n = 38) groups based on 75 g OGTT results. Maternal glucose, insulin, cytokines, and ProT-α levels were measured, and fetal growth was assessed by ultrasound at 20 wg, focusing on abdominal circumference (AC) and estimated fetal weight (EFW) percentiles. Results: Women with GDM were older, had a higher BMI, glucose, and insulin levels, with fetuses showing higher AC and EFW percentiles. IL-8, TNFα, and IL-1α were lower in the GDM group, while ProT-α was also lower but not significantly. ProT-α inversely correlated with EFW percentiles, independent of GDM. Regression analysis identified 2-hour post-load glucose, VEGF, and EGF as positive predictors of fetal growth acceleration, while IL-10 and ProT-α were negative predictors. Conclusions: Fetal growth is influenced by maternal glucose, inflammation, and angiogenesis. ProT-α may serve as an independent biomarker for predicting fetal growth in early pregnancy, suggesting further investigation into its role in GDM, obesity, and insulin resistance.

目的：研究胸腺素原-α (ProT-α)是一种免疫调节蛋白，作为妊娠糖尿病（GDM）胰岛素抵抗的潜在生物标志物，并作为妊娠20周（wg）胎儿生长的预测因子。方法：将46例单胎妊娠妇女分为GDM组（n = 8）和正常糖耐量组(NGT；根据75 g OGTT结果n = 38)组。测量母体葡萄糖、胰岛素、细胞因子和ProT-α水平，并在20 wg时通过超声评估胎儿生长情况，重点关注腹围（AC）和估计胎儿体重（EFW）百分位数。结果：患有GDM的女性年龄较大，BMI、葡萄糖和胰岛素水平较高，胎儿AC和EFW百分位数较高。GDM组IL-8、TNFα、IL-1α降低，ProT-α降低，但差异不显著。ProT-α与EFW百分位数呈负相关，与GDM无关。回归分析发现负荷后2小时葡萄糖、VEGF和EGF是胎儿生长加速的阳性预测因子，而IL-10和ProT-α是阴性预测因子。结论：胎儿生长受母体血糖、炎症和血管生成的影响。ProT-α可能作为预测妊娠早期胎儿生长的独立生物标志物，提示其在GDM、肥胖和胰岛素抵抗中的作用有待进一步研究。

{"title":"Predicting accelerated fetal growth in pregnancy: beyond maternal hyperglycemia – The role of prothymosin-α, inflammatory cytokines, and angiogenic factors","authors":"Maria Mirabelli , Marta Greco , Stefano Iuliano , Francesco Dragone , Eusebio Chiefari , Daniela Foti , Antonio Brunetti","doi":"10.1016/j.jcte.2025.100404","DOIUrl":"10.1016/j.jcte.2025.100404","url":null,"abstract":"<div><div><em>Aim</em>: This study investigates prothymosin-α (ProT-α), an immunomodulatory protein, as a potential biomarker for insulin resistance in gestational diabetes (GDM), and as a predictor of fetal growth by 20 weeks of gestation (wg). <em>Methods</em>: Forty-six women with singleton pregnancies were classified into GDM (n = 8) and normal glucose tolerance (NGT; n = 38) groups based on 75 g OGTT results. Maternal glucose, insulin, cytokines, and ProT-α levels were measured, and fetal growth was assessed by ultrasound at 20 wg, focusing on abdominal circumference (AC) and estimated fetal weight (EFW) percentiles. <em>Results</em>: Women with GDM were older, had a higher BMI, glucose, and insulin levels, with fetuses showing higher AC and EFW percentiles. IL-8, TNFα, and IL-1α were lower in the GDM group, while ProT-α was also lower but not significantly. ProT-α inversely correlated with EFW percentiles, independent of GDM. Regression analysis identified 2-hour post-load glucose, VEGF, and EGF as positive predictors of fetal growth acceleration, while IL-10 and ProT-α were negative predictors. <em>Conclusions</em>: Fetal growth is influenced by maternal glucose, inflammation, and angiogenesis. ProT-α may serve as an independent biomarker for predicting fetal growth in early pregnancy, suggesting further investigation into its role in GDM, obesity, and insulin resistance.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100404"},"PeriodicalIF":4.2,"publicationDate":"2025-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144365261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Corrigendum to “False negative rate and concordance of ThyGeNEXT®+ThyraMIR® testing with post-thyroidectomy histopathology” [J. Clin. Translat. Endocrinol. 40 (2025) 100396] “ThyGeNEXT®+ThyraMIR®检测与甲状腺切除术后组织病理学的假阴性率和一致性”的更正[J]。中国。诠释。内分泌，40 (2025)100396 [j]

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Clinical and Translational Endocrinology

Pub Date : 2025-06-01 DOI: 10.1016/j.jcte.2025.100397

Sobrina S. Mohammed , Daniel Mettman , Mariana Garcia-Touza , Betty Drees , Maricel Ridella

引用次数: 0

Corrigendum to “Prediction of BRAF and TERT status in PTCs by machine learning-based ultrasound radiomics methods: A multicenter study” [J. Clin. Translat. Endocrinol. 40 (2025) 100390] “基于机器学习的超声放射组学方法预测ptc的BRAF和TERT状态：一项多中心研究”[J]。中国。诠释。内分泌，40 (2025)100390 [j]

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Clinical and Translational Endocrinology

Pub Date : 2025-06-01 DOI: 10.1016/j.jcte.2025.100394

Hui Shi , Ke Ding , Xue Ting Yang , Ting Fan Wu , Jia Yi Zheng , Li Fan Wang , Bo Yang Zhou , Li Ping Sun , Yi Feng Zhang , Chong Ke Zhao , Hui Xiong Xu

引用次数: 0

Glucocorticoids: The culprit behind metabolic disorders in primary Aldosteronism? A narrative review 糖皮质激素：原发性醛固酮增多症代谢紊乱的罪魁祸首？叙述性回顾

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Clinical and Translational Endocrinology

Pub Date : 2025-05-28 DOI: 10.1016/j.jcte.2025.100401

Piotr Kmieć , Renata Świątkowska-Stodulska

In recent years, a new approach toward aldosterone secretion autonomy has emerged as a consequence of studies demonstrating its continuum from subclinical, mild to overt and severe forms. These clinical insights were accompanied by immense progress in deciphering the tissue and cellular pathology underlying primary aldosteronism (PA).

Thus far, research has not sufficiently elucidated the relationships between overt PA and metabolic disorders. Similarly, the role of glucocorticoid cosecretion in this patient group remains unclear. Milder than overt PA forms have been scarcely investigated.

This review critically analyzes these issues on the basis of a literature search of the PubMed database.

近年来，由于研究表明其从亚临床，轻度到明显和严重形式的连续统一体，出现了一种新的醛固酮分泌自主方法。这些临床见解伴随着对原发性醛固酮增多症（PA）的组织和细胞病理的巨大进展。到目前为止，研究还没有充分阐明显性PA与代谢紊乱之间的关系。同样，糖皮质激素共分泌在该患者组中的作用仍不清楚。比公开的PA形式更温和的形式几乎没有被调查过。这篇综述在PubMed数据库的文献检索基础上批判性地分析了这些问题。

引用次数: 0

Gender differences in psychosocial outcomes according to BMI among adults living with type 1 diabetes: A cross-sectional BETTER analysis 成人1型糖尿病患者根据BMI的心理社会结局的性别差异：一项横断面BETTER分析

IF 4.2 Q1 ENDOCRINOLOGY & METABOLISM

Journal of Clinical and Translational Endocrinology

Pub Date : 2025-05-23 DOI: 10.1016/j.jcte.2025.100400

Anne Bonhoure , Marie-Laure Lalanne-Mistrih , Meryem Talbo , Valérie Boudreau , Virginie Messier , Aude Bandini , Laurence Secours , Sonia Fontaine , Anne-Sophie Brazeau , Rémi Rabasa-Lhoret

Aims

The prevalence of overweight and obesity in people with type 1 diabetes has increased significantly, presenting additional psychosocial challenges that vary by gender. This study investigates the relationship between BMI and psychosocial outcomes in adult men and women with type 1 diabetes.

Methods

This cross-sectional analysis used data from people with type 1 diabetes in the BETTER registry, stratified by gender and categorized into BMI groups (<25, 25–29.9, ≥ 30 kg/m²). Psychosocial outcomes included depression, diabetes distress, and stigmatization related to diabetes. One-way ANOVA assessed differences between BMI groups by gender. Multivariable logistic regression then analyzed gender differences within each BMI group, adjusting for age and HbA1c.

Results

Among 1028 participants (66 % women, mean BMI 26.4 ± 5.1 kg/m², mean age 45.4 ± 15.0 years), 460 adults (45 %) had a BMI < 25, 356 (35 %) between 25–29.9, and 212 (21 %) ≥ 30 kg/m². Women in the ≥ 30 kg/m² group, compared to the < 25 kg/m² group, had more symptoms of depression, more drug prescriptions for depression/anxiety, and higher diabetes distress (p < 0.001 for all). In men, psychosocial outcomes did not differ significantly across BMI groups. Multivariable regression showed women were more likely than men to report prescriptions for depression/anxiety and high diabetes distress, particularly in the higher BMI groups.

Conclusions

In adults living with type 1 diabetes, higher BMI is associated with adverse psychosocial outcomes, particularly in women. Gender-specific interventions addressing mental health, stigma, and weight management could be beneficial to improve overall well-being.

1型糖尿病患者中超重和肥胖的患病率显著增加，这给性别带来了额外的心理社会挑战。本研究调查了1型糖尿病成年男性和女性BMI与心理社会结局之间的关系。方法：本横断面分析使用来自BETTER登记的1型糖尿病患者的数据，按性别分层并按BMI组（25、25 - 29.9、≥30 kg/m2）分类。社会心理结果包括抑郁、糖尿病困扰和与糖尿病相关的污名化。单因素方差分析按性别评估BMI组之间的差异。多变量逻辑回归分析了每个BMI组的性别差异，调整了年龄和HbA1c。结果在1028名参与者中（66%为女性，平均BMI为26.4±5.1 kg/m2，平均年龄为45.4±15.0岁），460名成年人（45%）有BMI和lt；25日,25 - 29.9之间356(35%),212(21%)≥30 kg / m2。≥30kg /m2组的女性，与25 kg/m2组，有更多的抑郁症状，更多的抑郁/焦虑药物处方，更高的糖尿病窘迫(p <；0.001)。在男性中，不同BMI组的心理社会结果没有显著差异。多变量回归显示，女性比男性更有可能报告抑郁/焦虑和高糖尿病困扰的处方，特别是在高BMI组中。结论在1型糖尿病成人患者中，较高的BMI与不良的社会心理结局相关，尤其是女性患者。针对心理健康、耻辱感和体重管理的性别干预措施可能有利于改善整体福祉。

{"title":"Gender differences in psychosocial outcomes according to BMI among adults living with type 1 diabetes: A cross-sectional BETTER analysis","authors":"Anne Bonhoure , Marie-Laure Lalanne-Mistrih , Meryem Talbo , Valérie Boudreau , Virginie Messier , Aude Bandini , Laurence Secours , Sonia Fontaine , Anne-Sophie Brazeau , Rémi Rabasa-Lhoret","doi":"10.1016/j.jcte.2025.100400","DOIUrl":"10.1016/j.jcte.2025.100400","url":null,"abstract":"<div><h3>Aims</h3><div>The prevalence of overweight and obesity in people with type 1 diabetes has increased significantly, presenting additional psychosocial challenges that vary by gender. This study investigates the relationship between BMI and psychosocial outcomes in adult men and women with type 1 diabetes.</div></div><div><h3>Methods</h3><div>This cross-sectional analysis used data from people with type 1 diabetes in the BETTER registry, stratified by gender and categorized into BMI groups (<25, 25–29.9, ≥ 30 kg/m<sup>2</sup>). Psychosocial outcomes included depression, diabetes distress, and stigmatization related to diabetes. One-way ANOVA assessed differences between BMI groups by gender. Multivariable logistic regression then analyzed gender differences within each BMI group, adjusting for age and HbA1c.</div></div><div><h3>Results</h3><div>Among 1028 participants (66 % women, mean BMI 26.4 ± 5.1 kg/m<sup>2</sup>, mean age 45.4 ± 15.0 years), 460 adults (45 %) had a BMI < 25, 356 (35 %) between 25–29.9, and 212 (21 %) ≥ 30 kg/m<sup>2</sup>. Women in the ≥ 30 kg/m<sup>2</sup> group, compared to the < 25 kg/m<sup>2</sup> group, had more symptoms of depression, more drug prescriptions for depression/anxiety, and higher diabetes distress (p < 0.001 for all). In men, psychosocial outcomes did not differ significantly across BMI groups. Multivariable regression showed women were more likely than men to report prescriptions for depression/anxiety and high diabetes distress, particularly in the higher BMI groups.</div></div><div><h3>Conclusions</h3><div>In adults living with type 1 diabetes, higher BMI is associated with adverse psychosocial outcomes, particularly in women. Gender-specific interventions addressing mental health, stigma, and weight management could be beneficial to improve overall well-being.</div></div>","PeriodicalId":46328,"journal":{"name":"Journal of Clinical and Translational Endocrinology","volume":"41 ","pages":"Article 100400"},"PeriodicalIF":4.2,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144221828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0